Tralokinumab 300 mg, Q2W
CD-RI-CAT-354-1049
Phase 2 mab completed
Quick answer
Tralokinumab 300 mg, Q2W for Asthma is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MedImmune
- Indication
- Asthma
- Phase
- Phase 2
- Modality
- mab
- Status
- completed